Dutch regulator investigates Biogen over MS drug blood test

The Netherlands’ competition regulator is investigating whether Biogen restricted access to a blood test used to assess a serious risk linked to its multiple sclerosis drug Tysabri. The ACM says the arrangement may hinder competitors and affect prices, supply and patient choice.












